Skip to content
Tenfell
Awarded contract
Published 29 Jul 2025

NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025

NHS England · London

Key facts

Awarded
30 Jun 2025
Contract starts
31 Aug 2025
Contract ends
31 Aug 2027
Procedure
Open procedure (above threshold)
Buyer type
Central government

Awarded to 21 suppliers

SupplierValue
FRESENIUS KABI LIMITED—
Takeda UK Limited—
Dr Reddy's Laboratories (UK) Ltd—
GlaxoSmithKline—
Janssen-Cilag Ltd—
Orifarm UK—
Pfizer Ltd—
Abbvie Ltd—
Amgen Ltd—
Sandoz Ltd—
Thornton & Ross Ltd—
Accord-UK Ltd—
Biogen—
Celltrion Healthcare United Kingdom Limited—
Organon Pharmaceuticals UK Ltd—
Roche Products Ltd—
Sobi (Swedish Orphan Biovitrum Ltd)—
Zentiva Pharma UK Ltd—
Samsung Bioepis Ltd—
Alexion Pharmaceuticals—
CuraTeQ Biologics s.r.o.—

Description

NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder (Open Government Licence v3.0). Always read the original notice before responding.